Basic understanding and therapeutic approaches to target toll‐like receptors in cancerous microenvironment and metastasis
Read more:
https://www.linkedin.com/feed/update/activity:6457304107924353024

@cip_usern

The promising role of monoclonal antibodies for
immunotherapy of the HIV-associated cancer, non-
Hodgkin lymphoma
For more:
https://www.linkedin.com/feed/update/urn:li:activity:6458647817702375424/

@cip_usern

Immunotherapy of cancers comes of age
Read more:
https://www.linkedin.com/feed/update/activity:6459428167022055424

@cip_usern

برگزاري جلسه معارفه و ارائه نحوه فعاليت پژوهشي در گروه Cancer Immunology Project

#سومين دوره جذب عضو گروه CIP
#عكس_دسته_جمعي
يكم آبان ٩٧
@cip_usern
@usern_net

Cancer cachexia: Diagnosis, assessment, and treatment
For more:
https://www.linkedin.com/feed/update/urn:li:activity:6461186794728759296/

@cip_usern

Passive-specific immunotherapy with monoclonal antibodies for prostate cancer: A systematic review
Read more:
https://www.linkedin.com/feed/update/activity:6463389187079962624

@cip_usern

Roles of Myeloid-Derived Suppressor Cells in Cancer Metastasis: Immunosuppression and Beyond.
Read more:
https://www.linkedin.com/feed/update/activity:6467041505277157376

Dermatofibrosarcoma Protuberans; Case Report of
a Rare Tumor of the Breast.
Read more:
https://www.linkedin.com/feed/update/activity:6469956210970890240

@cip_usern

Radioimmunotherapy in non-Hodgkin lymphoma: Prediction andassessment of response
Read more:
https://www.linkedin.com/feed/update/urn:li:activity:6477561315643662336/

📺 مصاحبه با دکتر رضایی در شبکه ۴ سيما، خبر ساعت ۲۰ در خصوص مراسم سالگرد تاسیس یوسرن

🏷اگر هنوز برای شرکت در این مراسم ثبت نام نکرده اید:

https://goo.gl/forms/GxbtlkFukJ5YJvQC3
یا
https://evnd.co/gUxEY

@usern_net

The promising role of monoclonal antibodies for gastric cancer treatment
Read more:
https://www.linkedin.com/feed/update/urn:li:activity:6501870827573649408

@cip_usern

IL-17 and colorectal cancer: From carcinogenesis to treatment.
Read more:
https://www.linkedin.com/feed/update/urn:li:activity:6510406463985324032/

@cip_usern

#آشنایی_با_اینترست_گروپ_یوسرن

⚜️گروه پژوهشی Cancer Immunology Project در سال 2016 تاسیس شد. این گروه با چاپ 14 مقاله و نگارش دو کتاب با همکاری Elsevier و Springer توانست عنوان برترین اینترست گروپ یوسرن را از آن خود کند.

کانال این گروه در تلگرام:
@cip_usern

ایمیل جهت برقراری ارتباط:
cip.usern@gmail.com

@usern_net

برآمد باد صبح و بوی نوروز
به کام دوستان و بخت پیروز

مبارک بادت این سال و همه سال
همایون بادت این روز و همه روز

گروه CIP فرا رسیدن سال نو را به شما همراهان گرامی تبریک عرض میکند🌸

@cip_usern

Therapeutic cancer vaccines represent a type of active cancer immunotherapy. Clinicians and scientists working on cancer treatment require evidence-based and up-to-date resources relating to therapeutic cancer vaccines.These vaccines provides a reference for cancer treatment for clinicians and presents a well-organized resource for determining high-potential research areas.
This book has been written by supervisors and members of CIP group and been published by Elsevier. Chapters cover cancer immunology, general approaches to cancer immunotherapy, vaccines, tumor antigens, the strategy of cancer vaccines, personalized vaccines, whole-tumor antigen vaccines, protein and peptide vaccines, dendritic cell vaccines, genetic vaccines, candidate cancers for vaccination, obstacles to developing therapeutic cancer vaccines, combination therapy, future perspectives and concluding remarks on therapeutic cancer vaccines.

https://www.elsevier.com/books/vaccines-for-cancer-immunotherapy/rezaei/978-0-12-814039-0

To understand the fundamental interactions between tumor cells and the immune system, immunosurveillance and evolutionally immunoediting hypothesis were proposed. When tumor cells overcome mechanisms of the immune system in the elimination phase, they proceed with the equilibrium and probably escape phases. In each phase, various immune cells and cytokines are involved. Moreover, several mechanisms are considered for the tumor escaping form the immune system, including defect in tumor antigen presentation and recognition, dominance of inhibitory mechanisms and lack of activating effects, and resistant subtypes of tumor cells such as cancer stem cells. 

Read more:
https://www.sciencedirect.com/science/article/pii/B9780128140390000011

https://www.linkedin.com/feed/update/urn:li:activity:6515570644556488704

@cip_usern

Cancer immunotherapy has a long history with the first evidence recorded in the late 19th century. Coley's toxin was firstly used in a patient with sarcoma, and with subsequent regression of the tumor, numerous questions raised. Immunosurveillance and, afterwards, immunoediting hypothesis were described in order to figure out the immune system/tumor cells interactions. In order to overcome tumor immune scape, the third phase of cancer immunoediting, and to empower elimination step, immunotherapeutic modalities have been developed. They can be addressed from different views such as classification according to active or passive and specific or nonspecific approach. Up to now, 40 immunotherapeutics have been approved for cancer treatment by the FDA for approximately 90 indications. The modalities include cytokines, toll-like receptor agonists, monoclonal antibodies (mAbs), radio-labeled mAbs, drug-conjugated mAbs, vaccine, immune checkpoint inhibitors, oncolytic virus, bispecific mAbs, and chimeric antigen receptor T cell therapy.

Read more:
https://www.sciencedirect.com/science/article/pii/B9780128140390000023

https://www.linkedin.com/feed/update/urn:li:activity:6518143579779665920/

@cip_usern

Vaccines have been used as a preventive modality against infectious disease for a long time. The application of vaccines to treat the diseases, which have interactions with the immune system, have revealed a new concept of immunotherapy, known as therapeutic vaccines. Many efforts have been made to utilize this modality in the most efficient way. To optimize the current vaccines, understanding the determinants such as selection of the appropriate antigens, combination of effective adjuvants, application of a delivery system, and administration through the proper route are necessary.

For more:
https://www.sciencedirect.com/science/article/pii/B9780128140390000035

https://www.linkedin.com/feed/update/urn:li:activity:6518474982987689984

@cip_usern

Tumor antigens are the central factors in development of vaccines. They can be delivered to the body along with antigen presenting cells(APCs), immune simulators and immune modulators. Due to availability of new technology, the first gene recognized by T cell, was reported to encode a human tumor antigen and then rapidly molecular identification and characterization of novel tumor-associated antigens (TAAs) and tumor-specific antigens (TSAs) including shared antigens, neoantigens, and unique antigens was developed. These antigens serve as a biomarker for identification of the tumor nature and developing novel cancer vaccines. 

For more:
https://www.sciencedirect.com/science/article/pii/B9780128140390000047

https://www.linkedin.com/feed/update/urn:li:activity:6519112999687462912

@cip_usern

Various clinical trials have been conducted to test autologous and allogeneic vaccines for treatment of different types of cancer. Autologous cancer vaccines include unique or rare tumor antigens that develop through mutational events. Allogeneic cancer vaccines, on the other hand, are comprised of intact or modified cancer cells from other patients selected for the presence of shared antigens found on a large percentage of similar tumor types. Their significant advantages are their availability for patients in all stages of the disease and provide the capability to administer multiple vaccinations over a protracted period. Until now, many clinical trials have been conducted but because of great heterogeneity present inter- and intratumorally, few positive results have been attained. 

For more:
https://www.sciencedirect.com/science/article/pii/B9780128140390000059

https://www.linkedin.com/feed/update/urn:li:activity:6519892954117607424

@cip_usern

Personalized medicine is going ahead toward clinical utilization. Due to the recent advances in the “omic” technologies, including genomic studies, the use of individualized approaches has progressed in various diseases including cancer. Individualization has also entered into the field of cancer immunotherapy. Seeking for and selecting the immunogenic neoantigens, which are personalized and unique tumor antigens caused by somatic mutations, is of interest to design specific immunotherapiesincluding vaccines. Recent achievements have been yielded in the clinical trials evaluating synthetic long peptide and poly-neo-epitope RNA vaccines for improvement of disease-free survival in patients at high risk of melanoma recurrence.

Read more:
https://www.sciencedirect.com/science/article/pii/B9780128140390000060

https://www.linkedin.com/feed/update/urn:li:activity:6520341222710616064

@cip_usern
@usern_net